19825950

Source:http://linkedlifedata.com/resource/pubmed/id/19825950

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0079459, umls-concept:C0205179, umls-concept:C0205390, umls-concept:C0280100, umls-concept:C0574032, umls-concept:C1511572, umls-concept:C1521801, umls-concept:C1831874, umls-concept:C2603343, umls-concept:C2700603
pubmed:issue	21
pubmed:dateCreated	2009-11-5
pubmed:abstractText	This study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the i.v. pan-aurora kinase inhibitor PHA-739358, danusertib, in patients with advanced solid tumors.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P30 CA006927, http://linkedlifedata.com/resource/pubmed/grant/P30 CA006927-47
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzamides, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/PHA 739358, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/aurora kinase
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1078-0432
pubmed:author	pubmed-author:AggarwalCharuC, pubmed-author:BurrisHoward AHA, pubmed-author:CerutiRobertaR, pubmed-author:ChengJonathanJ, pubmed-author:CohenRoger BRB, pubmed-author:ComisSilviaS, pubmed-author:GrecoF AnthonyFA, pubmed-author:JonesSuzanne FSF, pubmed-author:LaffranchiBernardB, pubmed-author:MarianiMariangelaM, pubmed-author:MollJurgenJ, pubmed-author:RocchettiMaurizioM, pubmed-author:SpigelDavid RDR, pubmed-author:von MehrenMargaretM
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	15
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	6694-701
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19825950-Adult, pubmed-meshheading:19825950-Aged, pubmed-meshheading:19825950-Aged, 80 and over, pubmed-meshheading:19825950-Antineoplastic Agents, pubmed-meshheading:19825950-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19825950-Benzamides, pubmed-meshheading:19825950-Drug Administration Schedule, pubmed-meshheading:19825950-Enzyme Inhibitors, pubmed-meshheading:19825950-Female, pubmed-meshheading:19825950-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:19825950-Humans, pubmed-meshheading:19825950-Infusions, Intravenous, pubmed-meshheading:19825950-Male, pubmed-meshheading:19825950-Middle Aged, pubmed-meshheading:19825950-Neoplasms, pubmed-meshheading:19825950-Neutropenia, pubmed-meshheading:19825950-Protein-Serine-Threonine Kinases, pubmed-meshheading:19825950-Pyrazoles, pubmed-meshheading:19825950-Recombinant Proteins
pubmed:year	2009
pubmed:articleTitle	A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
pubmed:affiliation	Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. rb_cohen@fccc.edu
pubmed:publicationType	Journal Article, Clinical Trial, Phase I, Research Support, N.I.H., Extramural